Amare Gashaw Azanaw, Wondmagegn Yenesew Mihret, Setegn Abebaw, Belayneh Mekuriaw, Muche Yalew, Melkamu Abateneh, Misgana Kassahun, Ashagre Agenagnew, Baylie Temesgen, Jemal Mohammed, Getinet Mamaru, Fenta Abebe, Belew Habtamu, Adugna Adane
Department of Medical Laboratory Science, Debre Markos University, Debre Markos, Ethiopia.
Department of Medical Parasitology, University of Gondar, Gondar, Ethiopia.
BMC Infect Dis. 2025 May 12;25(1):691. doi: 10.1186/s12879-025-11070-7.
Strongyloidiasis caused by the parasite Strongyloides stercoralis, is a significant public health issue, particularly in low-income countries with inadequate sanitation practices. Ivermectin is the recommended drug by the World Health Organization for treating S. stercoralis infection, but its efficacy in Ethiopia has not been extensively studied. This study aimed to assess the effectiveness of Ivermectin treatment for S. stercoralis infection in adult patients.
A cross-sectional study was conducted in government hospitals in northwest Ethiopia from June 2022 to February 2024. A total of 190 patients confirmed to be infected with S. stercoralis were treated with Ivermectin (200 µg/kg) for two days. Stool samples were collected two weeks after treatment and analyzed using parasitological concentration techniques.
The cure rate was 90% among the treated individuals, demonstrating a significant reduction in the prevalence of S. stercoralis infection. Among the cases that were not cured, the majority were older individuals, with a higher proportion (66.8%) residing in rural areas. A small number of non-cured individuals experienced persistent symptoms after treatment. All individuals who successfully cleared the infection were asymptomatic.
The study found a 90% cure rate for the current 2-day Ivermectin treatment regimen (200 µg/kg) against Strongyloides stercoralis in Ethiopia, suggesting the recommended strategy is appropriate. Age, residential area, and other factors have been found to influence treatment outcomes, warranting further investigation into potential resistance factors and optimizing treatment for different populations.
由寄生虫粪类圆线虫引起的粪类圆线虫病是一个重大的公共卫生问题，在卫生设施不完善的低收入国家尤为突出。伊维菌素是世界卫生组织推荐用于治疗粪类圆线虫感染的药物，但在埃塞俄比亚其疗效尚未得到广泛研究。本研究旨在评估伊维菌素治疗成年患者粪类圆线虫感染的有效性。
2022年6月至2024年2月在埃塞俄比亚西北部的政府医院进行了一项横断面研究。共有190名确诊感染粪类圆线虫的患者接受了为期两天的伊维菌素（200μg/kg）治疗。治疗两周后收集粪便样本，并使用寄生虫学浓缩技术进行分析。
治疗个体的治愈率为90%，表明粪类圆线虫感染率显著降低。在未治愈的病例中，大多数是老年人，居住在农村地区的比例较高（66.8%）。少数未治愈的个体在治疗后仍有持续症状。所有成功清除感染的个体均无症状。
该研究发现，目前在埃塞俄比亚采用的为期两天的伊维菌素治疗方案（200μg/kg）治疗粪类圆线虫的治愈率为90%，表明推荐的治疗策略是合适的。已发现年龄、居住地区和其他因素会影响治疗结果，有必要进一步调查潜在的耐药因素，并针对不同人群优化治疗方案。
